Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Bingcao Wu, Erik Muser, Amanda Teeple, Christopher D. Pericone & Steven R. Feldman. (2021) Treatment adherence and persistence of five commonly prescribed medications for moderate to severe psoriasis in a U.S. commercially insured population. Journal of Dermatological Treatment 32:6, pages 595-602.
Read now
Read now
Mwangi J. Murage, Adrienne M. Gilligan, Oth Tran, Orin Goldblum, Russel Burge, Chen-Yen Lin & Abrar Qureshi. (2021) Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis. Journal of Dermatological Treatment 32:1, pages 56-63.
Read now
Read now
Sara Higa, Beth Devine, Vaishali Patel, Sarah Baradaran, Degang Wang & Aasthaa Bansal. (2019) Psoriasis treatment patterns: a retrospective claims study. Current Medical Research and Opinion 35:10, pages 1727-1733.
Read now
Read now
Mwangi J Murage, Vanita Tongbram, Steven R Feldman, William N Malatestinic, Cynthia J Larmore, Talia M Muram, Russel T Burge, Charles Bay, Nicole Johnson, Sarah Clifford & Andre B Araujo. (2018) Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Preference and Adherence 12, pages 1483-1503.
Read now
Read now
G. Carretero, L. Puig, J. M. Carrascosa, L. Ferrándiz, R. Ruiz-Villaverde, P. de la Cueva, I. Belinchon, E. Vilarrasa, R. del Rio, J. L. Sánchez-Carazo, A. López-Ferrer, F. Peral, S. Armesto, N. Eiris, J. Mitxelena, J. Vilar-Alejo, M. A. Martin & C. Soria. (2018) Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. Journal of Dermatological Treatment 29:4, pages 334-346.
Read now
Read now
Lauren Seale, Leah A. Cardwell & Steven R. Feldman. (2018) Adherence to biologics in patients with psoriasis. Expert Review of Clinical Immunology 14:2, pages 155-161.
Read now
Read now
Articles from other publishers (12)
Unnikrishnan M. Chandrasekharan, Raminderjit Kaur, Jennifer E. Harvey, Chad Braley, Vandana Rai, MacKenzie Lee, Nicholas de Windt, Jason Hsieh, Ritika Jaini, Defne Bayik, Rachel G. Scheraga, Anthony P. Fernandez, Paul E. DiCorleto & M. Elaine Husni. (2022) TNFR2 Depletion Reduces Psoriatic Inflammation in Mice by Downregulating Specific Dendritic Cell Populations in Lymph Nodes and Inhibiting IL-23/IL-17 Pathways. Journal of Investigative Dermatology 142:8, pages 2159-2172.e9.
Crossref
Crossref
Eugenia Piragine, Davide Petri, Alma Martelli, Agata Janowska, Valentina Dini, Marco Romanelli, Vincenzo Calderone & Ersilia Lucenteforte. (2022) Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. Journal of Clinical Medicine 11:6, pages 1506.
Crossref
Crossref
Joeseph Nenow, Esthe Balogh & Steven Feldman. (2021) Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?. EMJ Dermatology, pages 106-121.
Crossref
Crossref
Alessio Gambardella, Gaetano Licata & Anne Sohrt. (2021) Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review. Dermatology and Therapy 11:4, pages 1141-1156.
Crossref
Crossref
Aaminah Azhar, Marcus Zaayman, Annika Silfvast‐Kaiser, Dario Kivelevitch, Alan Menter & So Yeon Paek. (2020) Ixekizumab in the treatment of moderate‐to‐severe plaque psoriasis: Patient adherence, satisfaction, and preferences. Dermatologic Therapy 34:1.
Crossref
Crossref
D. Rigopoulos, D. Ioannides, G. Chaidemenos, P. Kallidis, A. Voultsidou, A. Matekovits & E. Soura. (2018) Patient preference study for different characteristics of systemic psoriasis treatments (Protimisis). Dermatologic Therapy 31:3.
Crossref
Crossref
Antonio Costanzo, Giovanna Malara, Claudio Pelucchi, Francesco Fatiga, Giovanna Barbera, Andrea Franchi & Carlotta Galeone. (2018) Effectiveness End Points in Real-World Studies on Biological Therapies in Psoriasis: Systematic Review with Focus on Drug Survival. Dermatology 234:1-2, pages 1-12.
Crossref
Crossref
Robert E. Kalb. 2018. Biologic and Systemic Agents in Dermatology. Biologic and Systemic Agents in Dermatology
73
82
.
Saakshi Khattri, Patrick M. Brunner, Sandra Garcet, Robert Finney, Steven R. Cohen, Margeaux Oliva, Riana Dutt, Judilyn Fuentes-Duculan, Xiuzhong Zheng, Xuan Li, Kathleen M. Bonifacio, Norma Kunjravia, Israel Coats, Inna Cueto, Patricia Gilleaudeau, Mary Sullivan-Whalen, Mayte Suárez-Fariñas, James G. Krueger & Emma Guttman-Yassky. (2017) Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Experimental Dermatology 26:1, pages 28-35.
Crossref
Crossref
A. Menter, K.A. Papp, M. Gooderham, D.M. Pariser, M. Augustin, F.A. Kerdel, S. Fakharzadeh, K. Goyal, S. Calabro, W. Langholff, S. Chavers, D. Naessens, J. Sermon & G.G. Krueger. (2016) Drug survival of biologic therapy in a large, disease‐based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). Journal of the European Academy of Dermatology and Venereology 30:7, pages 1148-1158.
Crossref
Crossref
Jalpa A. Doshi, Junko Takeshita, Lionel Pinto, Penxiang Li, Xinyan Yu, Preethi Rao, Hema N. Viswanathan & Joel M. Gelfand. (2016) Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. Journal of the American Academy of Dermatology 74:6, pages 1057-1065.e4.
Crossref
Crossref
John K. Nia & Mark G. Lebwohl. 2016. Therapy for Severe Psoriasis. Therapy for Severe Psoriasis
127
137
.